Indium (In111) Chloride Curium Netherlands (Indium (111in) Chloride)

After intravenous injection, Indium-111 chloride distributes throughout the extracellular fluid and preferentially accumulates in areas with increased vascular permeability or reticuloendothelial activity. The isotope emits gamma photons that are detected by a gamma camera, creating detailed images of the targeted tissues.

The administered activity of Indium-111 chloride is determined by the prescribing physician based on the specific diagnostic indication, patient weight, and imaging protocol. Dosage is individualized and should follow the relevant nuclear medicine guidelines.

Safety data for Indium-111 chloride in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks to the fetus or infant. Clinicians should discuss possible alternatives and obtain informed consent.

To request Indium (In111) Chloride, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Indium-111 chloride offers a longer half‑life (≈2.8 days) and gamma emission suitable for high‑resolution imaging, making it advantageous for delayed imaging of inflammation, infection and tumor localization compared with shorter‑lived agents like Technetium‑99m. However, it requires careful radiation safety management and may be less suitable for rapid‑turnaround studies.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be kept in its original container until use and handled by trained personnel using appropriate radiation safety measures.

Indium-111 chloride is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The injection is typically performed in a controlled nuclear medicine suite with appropriate shielding and monitoring.

Serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and rare radiation‑induced tissue injury. Prompt recognition and management of these events are essential, and patients should be monitored closely after administration.

Indium-111 chloride should be avoided in patients with known hypersensitivity to the product, those who are pregnant unless absolutely necessary, and individuals with severe renal impairment without appropriate dose adjustment. It is also contraindicated when concurrent administration of other gamma‑emitting radiopharmaceuticals would interfere with diagnostic interpretation.